Symbols

TSHA

Taysha Gene·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Strong Buy"

MACD Death Cross

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TSHA

Taysha Gene Therapies, Inc.

A clinical-stage gene therapy company focused on developing treatments for rare genetic diseases

Industry

Biological Technology

Established Date

09/20/2019

Listing Date

09/24/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.tayshagtx.com

Security Type

Common stock

Office address

3000 Pegasus Park Dr. Ste 1430, Dallas, Texas 75247

Business

Introduction

Taysha Gene Therapies, Inc. was originally incorporated under Texas law on September 20, 2019. The Company was converted to a Delaware corporation on February 13, 2020. The Company is a patient-centric gene therapy company dedicated to the development and development of commercialized AAV-based gene therapies for the treatment of rare and large patient populations of central nervous system monogenic diseases.

Company Financials

EPS

TSHA has released its 2025 Q4 earnings. EPS was reported at -0.08, versus the expected -0.1, beating expectations. The chart below visualizes how TSHA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TSHA has released its 2025 Q4 earnings report, with revenue of 5.49M, reflecting a YoY change of 171.27%, and net profit of -27.85M, showing a YoY change of -48.26%. The Sankey diagram below clearly presents TSHA's revenue sources and cost distribution.